The U.S. District Court for the District of Oregon recently issued a permanent injunction against James G. Cole Inc., manufacturer of products under the name “Maxam Nutraceutics,” to prevent the distribution of unapproved and misbranded drugs and adulterated dietary supplements. The Department of Justice filed a complaint, at the request of the Food and Drug Administration (FDA), alleging that the company was manufacturing dietary supplements under conditions that were inadequate to ensure the quality of the products and that the products were unapproved and misbranded. The court’s decision was based in part on the company’s claims that its products could treat autism, Alzheimer’s, HIV, and fibromyalgia, among other diseases. The court also found that the company’s products were misbranded because they failed to bear adequate directions for use and were adulterated because they were not produced in compliance with federal good manufacturing practice regulations.